Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequence variation in PPARG may underlie differential response to troglitazone.

Diabetes - 1 Nov 2005

Wolford Johanna K, Yeatts Kimberly A, Dhanjal Sharanjeet K, Black Mary Helen, Xiang Anny H, Buchanan Thomas A, Watanabe Richard M

Abstract excerpt

Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-gamma (PPARG) agonists used to treat type 2 diabetes. TZDs can also be used to reduce rates of type 2 diabetes in at-risk individuals. However, a large fraction of TZD-treated patients (30-40%) do not respond to TZD treatment with an improvement in insulin sensitivity (Si). We hypothesized that variation within the gene encoding PPARG may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromans
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Linkage Disequilibrium

Share to Pharmacogenetics

Share to PPAR gamma

Share to Thiazolidinediones

Share to Time Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 16249460
DOI: 10.2337/diabetes.54.11.3319
PMCID: PMC2923445

Genes

PPARG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequence variation in PPARG may underlie differential response to troglitazone.PMID 16249460Read ↗

Pharmacogenetics of thiazolidinedione therapy.Semantic proximity Read ↗

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.Semantic proximity Read ↗

Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.Semantic proximity Read ↗

Genetics: Response to antidiabetic drugs affected by SNPs that alter genomic binding of PPARγ.Semantic proximity Read ↗

Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.Semantic proximity Read ↗

Novel insulin sensitizers: pharmacogenomic aspects.Semantic proximity Read ↗

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.Semantic proximity Read ↗

Response to micronized fenofibrate treatment is associated with the peroxisome???proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetesSemantic proximity Read ↗

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.Semantic proximity Read ↗

Pharmacogenomics and Pharmacogenetics of Thiazolidinediones: Role in Diabetes and Cardiovascular Risk FactorsSemantic proximity Read ↗

Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.Semantic proximity Read ↗

PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.